Showing 11-20 of 41 results for "".
The Horizon of Aesthetic Treatments
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-horizon-of-aesthetic-treatments/19036/Dina Anderson, MD, FAAD, takes a look at the future of aesthetic procedures, particularly treatments for submental fat as well as the ocular area that may play a major role in shaping the spectrum of aesthetic procedures.The Evolution of Injectables
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/anderson-2--apolesod/19038/Dina Anderson, MD, FAAD, discusses the changing landscape of injectable agents and how patients are more informed about various products and procedures.2014 Year in Review: Innovation in Laser & Light
https://practicaldermatology.com/topics/practice-management/2014-year-in-review-innovation-in-laser-light--iledirim/19004/R. Rox Anderson, MD reflects on the meaning of innovation and discusses why dermatology as a specialty is home to many important advances in the field of laser and light therapy.Management of the Periocular Area
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/management-of-the-periocular-area/19210/Richard Anderson, MD reviews his presentation on the proper approach to cosmetic management of the periocular area and mid-face at Vegas Cosmetic Surgery 2013. He discusses blepharoplasty, toxins, fillers, and more. VCS2013- Study: Psoriasis Not Caused by Somatic Mutationshttps://practicaldermatology.com/news/study-psoriasis-not-caused-by-somatic-mutations/2462099/Psoriasis is not caused or spread by spontaneous genetic mutations in the skin, new research suggests. Researchers from the Wellcome Sanger Institute in Hinxton, U.K. and collaborators sequenced skin samples from 111 people with psoriasis. They didn’t find any mutated genes in the psoriatic patche…
- ESMO News: Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%https://practicaldermatology.com/news/esmo-news-major-pathologic-response-to-neoadjuvant-pembrolizumab-in-advanced-melanoma-trial-exceeds-50/2462089/In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant pembrolizumab. These and other results of th…
- Drs. Jedd D. Wolchok and Lisa Newman Elected to National Academy of Medicinehttps://practicaldermatology.com/news/drs-jedd-d-wolchok-lisa-newman-elected-to-national-academy-of-medicine/2462055/Melanoma specialist Dr. Jedd D. Wolchok, the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, in partnership with NewYork-Presbyterian, and Dr. Lisa Newman, chief of the section of breast surgery at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell …
- AAD Survey: Too Few Folks Use Sun Protection During Outdoor Activitieshttps://practicaldermatology.com/news/aad-survey-too-few-folks-use-sun-protection-during-outdoor-activities/2461735/Although 90% of Americans report protecting themselves from the sun when going to beaches or pools, far fewer plan for it before other outdoor activities, according to a recent American Academy of Dermatology (AAD) survey of more than 1,000 U.S. adults. "The head, neck, arms, and lower legs are ar…
- Landmark Data: Neoadjuvant Pembrolizumab Improves Outcomes for High-risk Melanoma Patientshttps://practicaldermatology.com/news/landmark-data-neoadjuvant-pembrolizumab-improves-outcomes-for-high-risk-melanoma-patients/2461589/Patients with high-risk melanoma who received pembrolizumab both before and after surgery had a significantly lower risk of their cancer recurring than patients who received the drug only after surgery. These results, published today in the New England Journal of Medicine, are from a research stud…
- FDA Clears the Accure Laser System for the Treatment of Mild to Severe Inflammatory Acne Vulgarishttps://practicaldermatology.com/news/fda-clears-the-accure-laser-system-for-the-treatment-of-mild-to-severe-inflammatory-acne-vulgaris/2461439/The FDA has cleared Accure Acne Inc's Accure Laser System to treat mild to severe inflammatory acne vulgaris. The Accure Laser System builds upon the unique selectivity of the 1726nm laser wavelength, adding proprietary technology to precisely control thermal gradient depth. This technology breakth…